Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance ... that is specific to the subcutaneous form. In a statement, Eisai and Biogen said ...
The VHA website states that veterans who request lecanemab must be over 65, sign a consent form, have been diagnosed ... VHA will be paying for the drug. Leqembi’s annual list price is $26,500.
Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback